Responses
Regular and Young Investigator Award Abstracts
Clinical Trial Completed
614 Safety and efficacy of YBL-006, a novel anti-PD-1 antibody, in advanced solid tumors including G3 NET/NEC: results from a phase 1/2A study
Compose a Response to This Article
Other responses
No responses have been published for this article.
